Intracranial arteriosclerosis
disease diseaseOn this page
Summary
Intracranial arteriosclerosis (MONDO:0001632) is a disease and 14 clinical trials. Top therapeutic interventions include desmopressin, ezetimibe, and vitamin e. A subtype of arteriosclerosis disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | intracranial arteriosclerosis |
| Mondo ID | MONDO:0001632 |
| MeSH | D002537 |
| DOID | DOID:13097 |
| UMLS | C0007771 |
| MedGen | 3319 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of arteriosclerosis disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › arteriosclerosis disorder › intracranial arteriosclerosis
Related subtypes (4): Monckeberg arteriosclerosis, intermittent vascular claudication, atherosclerosis, arteriosclerotic retinopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 7 |
| PHASE4 | 3 |
| PHASE3 | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06243133 | PHASE4 | NOT_YET_RECRUITING | Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis |
| NCT07605130 | PHASE4 | NOT_YET_RECRUITING | Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial |
| NCT04325932 | PHASE4 | WITHDRAWN | Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis |
| NCT05047172 | PHASE3 | ACTIVE_NOT_RECRUITING | Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
| NCT06925971 | PHASE3 | NOT_YET_RECRUITING | A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM） |
| NCT00000600 | PHASE2 | TERMINATED | Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up |
| NCT04103034 | PHASE1 | COMPLETED | A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers |
| NCT05653505 | Not specified | NOT_YET_RECRUITING | Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis |
| NCT05692882 | Not specified | RECRUITING | A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China |
| NCT00200785 | Not specified | COMPLETED | Identifying the Anti-Blood-Clotting Compounds in Garlic |
| NCT02485275 | Not specified | COMPLETED | Stroke Imaging Package Study |
| NCT05063630 | Not specified | UNKNOWN | Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke |
| NCT05719883 | Not specified | COMPLETED | Evaluating the Safety and Efficacy of the Maurora® DES in ICAS |
| NCT06857045 | Not specified | WITHDRAWN | Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DESMOPRESSIN | 4 | 1 |
| EZETIMIBE | 4 | 1 |
| VITAMIN E | 4 | 1 |
| RECATICIMAB | 3 | 1 |
| RONDAPTIVON PEGOL | 2 | 1 |
| ALPHA-TOCOPHEROL | 0 | 1 |
Related Atlas pages
- Drugs: Desmopressin, Ezetimibe, Vitamin E, Recaticimab